Literature DB >> 25824806

Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor.

Yujun Dong1, Mingyue Wang2, Lin Nong3, Lihong Wang1, Xinan Cen1, Wei Liu1, Sainan Zhu4, Yuhua Sun1, Zeyin Liang1, Yuan Li1, Jinping Ou1, Zhixiang Qiu1, Hanyun Ren1.   

Abstract

This study retrospectively collected the clinical and laboratory data of 114 patients with Castleman disease (CD) from a single medical centre. Clinical classification identified 62 patients (54·4%) with unicentric Castleman disease and 52 (45·6%) with multi-centric Castleman disease. Pathological classification revealed 68 cases (59·6%) of hyaline vascular variant, 16 (14·1%) mixed cellular variant (Mix) and 30 (26·3%) plasmacytic variant. Clinical complications occurred in 69 CD patients, including 37 cases of paraneoplastic pemphigus (PNP) and 25 cases with renal complications. Haematological involvement, pleural effusion and/or ascites and POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) were also found. Univariate analysis showed that presence of clinical complications and PNP were both risk factors relating to CD patient survival. Prognostic factors showing P < 0·15 in univariate analysis and those with clinical significance were subjected to multivariate analysis using a Cox regression model. PNP presence and age over 40 years both significantly adversely affected survival. Thus, only presence of PNP was identified as an independent unfavourable survival risk factor in both univariate and multivariate analyses. Overall, the present data provide a panoramic description of CD cases and emphasize that the presence of PNP is an adverse prognostic factor.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Castleman disease; clinical complications; paraneoplastic pemphigus; prognostic factors; survival analysis

Mesh:

Year:  2015        PMID: 25824806     DOI: 10.1111/bjh.13378

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

2.  Presentation and Outcome of Castleman's Disease in Immunocompetent Hosts.

Authors:  Gaurav Prakash; Amanjeet Bal; Pankaj Malhotra; Vaishali Aggarwal; Alka Khadwal; Vikas Suri; Sanjay Jain; Savita Kumari; Radhika Srinivasan; Ashim Das; Neelam Varma; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-01       Impact factor: 0.900

3.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

4.  Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Authors:  Wanying Liu; Qingqing Cai; Tiantian Yu; Paolo Strati; Frederick B Hagemeister; Qiongli Zhai; Mingzhi Zhang; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbian Qian; Noriko Iwaki; Yasuharu Sato; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young; Li Yu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

5.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

6.  Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.

Authors:  Yibo Hua; Chao Liang; Jie Yang; Luyang Wang; Aimin Xu; Lei Xi; Shangqian Wang; Zengjun Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

7.  Retrospective analysis of 45 cases of localized retroperitoneal Castleman disease from a single center.

Authors:  Jian-Qiang Tang; He-Kai Chen; Xin Wang; Ming-Yue Wang; Yan Xiong; He Wang; Yin-Mo Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

8.  Features and Risk Factors for Paraneoplastic Autoimmune Multiorgan Syndrome in 145 Chinese Patients.

Authors:  Mingyue Wang; Furong Li; Xintong Wang; Xue Wang; Rui Wang; Yinmo Yang; Jian Li; Shijie Zhang; Weiming Huang; Yujun Dong; Xiangdong Mu; Ting Li; Kaiwen Ni; Xixue Chen; Xuejun Zhu
Journal:  Acta Derm Venereol       Date:  2020-11-04       Impact factor: 3.875

9.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

10.  Castleman's disease: Laparoscopic resection of unicentric disease in the hepatic hilum: A case report.

Authors:  Frans Serpa Carmoma; Marta Cueva; Frans Serpa Carmoma; Gabriel A Molina; Alberto Yu Lee; Emilia Flores
Journal:  Ann Med Surg (Lond)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.